• Bellevue Group flagged ASCO 2026 results already presented showing chemotherapy-sparing lung cancer regimens gaining momentum in frontline treatment.
• New targeted approaches outperformed established chemo-immunotherapy benchmarks, strengthening the investment case for companies spanning both ADC and PD-1/VEGF platforms.
• Revolution Medicines’ daraxonrasib posted Phase III results in previously treated pancreatic cancer that beat standard chemotherapy, supporting a potential shift in second-line care.
• Investor focus moved from proof of efficacy to speed of adoption and broader read-through for RAS-targeted oncology programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bellevue Group AG published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.